“This book by Dr. Charles Theuer and his colleagues offers an innovative approach to drug development. The core of the new approach, an independent CRO model, promises to enable life science companies to develop new medicines faster, with less expense, and without sacrificing quality. The book is a must-read for anyone in the industry interested in bringing new medicines to market.” —JOHN COGAN, PHD Former Lead Independent Director, Gilead Sciences, Inc.; Senior Fellow, Hoover Institution, Stanford University

“High quality drug candidates are increasingly being discovered abroad that have adequate patent protection and can serve as a foundation for accelerated drug development. As foreign sources become more sophisticated and aligned with FDA preclinical requirements, this approach will only become more attractive. Dr. Theuer and his colleagues at TRACON present a cost-efficient drug development platform that solves the problem of accessing the US pharmaceutical market for foreign firms by providing a return on investment even on drugs intended for rare diseases, while simultaneously benefitting US patients.” — BILL RASTETTER, PHD Chairman, Neurocrine Biosciences, Fate Therapeutics, Daré Bioscience, and San Diego Squared; past Chairman, Biogen Idec and Illumina